Metagenomi Therapeutics Inc (MGX)

NASD · Healthcare · Biotechnology · USA

Metagenomi Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Metagenomi Therapeutics is an in vivo genome editing company that develops curative genetic medicines using proprietary gene editing technologies discovered through metagenomics. The company creates novel nucleases and editing systems to correct genetic mutations throughout the human genome, with its lead program, MGX-001, targeting hemophilia A, and additional programs addressing secreted protein deficiencies and cardiometabolic diseases through partnerships.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Metagenomi Therapeutics Inc stock.

Our verdict on MGX

Undervalued: intrinsic value $2.72 per share, market price $0.63, margin of safety 76.8% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $2.72; the price of $0.63 is 77% below that value.

ETFs with the most weight in MGX

More on MGX

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than MGX in Biotechnology

Is MGX undervalued or overvalued?

MGX is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.72; the price of $0.63 is 77% below that value.

What is the intrinsic value of MGX?

$2.72 per share (as of the 2026-11-17 close), against a market price of $0.63. That is a margin of safety of 76.8%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.